ADMA Biologics Inc (NASDAQ:ADMA) – Research analysts at Zacks Investment Research issued their Q2 2017 earnings per share (EPS) estimates for ADMA Biologics in a report released on Tuesday. Zacks Investment Research analyst J. Vandermosten expects that the biotechnology company will post earnings of ($0.30) per share for the quarter. Zacks Investment Research also issued estimates for ADMA Biologics’ Q3 2017 earnings at ($0.15) EPS, Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.90) EPS, FY2018 earnings at ($0.01) EPS and FY2019 earnings at $1.37 EPS.
Separately, Maxim Group upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Monday, January 23rd.
TRADEMARK VIOLATION NOTICE: This story was first posted by Mideast Time and is the property of of Mideast Time. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.mideasttime.com/brokers-issue-forecasts-for-adma-biologics-incs-q2-2017-earnings-adma/1709273.html.
Shares of ADMA Biologics (NASDAQ:ADMA) opened at 3.74 on Thursday. The stock’s 50 day moving average is $4.46 and its 200 day moving average is $4.96. The company’s market capitalization is $48.19 million. ADMA Biologics has a 12 month low of $3.71 and a 12 month high of $8.00.
ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Friday, May 12th. The biotechnology company reported ($0.51) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.23. The firm had revenue of $2.63 million for the quarter, compared to the consensus estimate of $3.35 million. ADMA Biologics had a negative net margin of 198.45% and a negative return on equity of 6,405.90%.
Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in ADMA Biologics by 1.2% in the first quarter. Geode Capital Management LLC now owns 23,558 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 276 shares in the last quarter. Spark Investment Management LLC boosted its position in ADMA Biologics by 24.6% in the third quarter. Spark Investment Management LLC now owns 39,000 shares of the biotechnology company’s stock valued at $282,000 after buying an additional 7,700 shares in the last quarter. Vanguard Group Inc. boosted its position in ADMA Biologics by 3.2% in the first quarter. Vanguard Group Inc. now owns 150,028 shares of the biotechnology company’s stock valued at $732,000 after buying an additional 4,634 shares in the last quarter. Iguana Healthcare Management LLC boosted its position in ADMA Biologics by 20.0% in the third quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the biotechnology company’s stock valued at $1,086,000 after buying an additional 25,000 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new position in ADMA Biologics during the fourth quarter valued at about $3,692,000. Hedge funds and other institutional investors own 73.57% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.